<DOC>
	<DOCNO>NCT00859755</DOCNO>
	<brief_summary>This Phase 1 study , involve 1-day dosing period , design test safety investigational study drug ARRY-403 patient Type 2 diabetes . Approximately 36 patient US enrol study .</brief_summary>
	<brief_title>A Safety Study ARRY-403 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Key Male female willingness ability use protocolspecified method contraception , except female nonchildbearing potential . Diagnosis Type 2 diabetes less 5 year prior study start . HbA1c ≥ 6.5 % ≤ 10 % . BMI ≥ 25 ≤ 40.0 kg/m2 . Additional criterion exist . Key Recent history ( i.e. , less 6 month ) concomitant/ongoing clinically significant hematologic , renal , pulmonary , gastrointestinal , hepatic , psychiatric , neurologic , dermatologic , allergic disease ( include drug allergy clinically significant remote , exclude untreated , asymptomatic , seasonal allergy time dose ) . Significant cardiac disease , myocardial infarction within 6 month study start , unstable angina , congestive heart failure , know arrhythmia ventricular etiology , unexplained syncope syncope/seizures relate arrhythmia . History gastric surgery , vagotomy , bowel resection , surgical procedure might interfere gastrointestinal motility , pH , absorption . Active infectious disease include hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) . Past history inactive hepatitis B C , confirm serological testing , allow . A positive test drug alcohol . Women pregnant breastfeeding . Donation loss ≥ 550 mL blood ( include plasmapheresis ) receipt transfusion blood product within 8 week prior first dose study drug . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>